Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis Pipeline Review, H1 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.
(blechnews) - Albany, New York, 11 May, 2017: Global Markets Direct''s latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis Pipeline Review, H1 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.
Request For Free Sample (at) http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068021
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.
Global Markets Direct''s Pharmaceutical and Healthcare latest pipeline guide Psoriasis Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 21, 44, 42, 1, 103, 32 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively.
Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
Browse Full Report With TOC (at) http://www.marketresearchhub.com/report/psoriasis-pipeline-review-h1-2017-report.html
- Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
90 State Street,
Albany, NY 12207,
Toll Free: 866-997-4948 (US-Canada)
Follow Us on:
Datum: 11.05.2017 - 17:54
Anzahl Zeichen: 0
Firma: Market Research HUB
Direkter Link zu dieser Meldung:
Über einen Link auf Ihrer News-, Presse- oder Partner-Seite würden wir uns sehr freuen.